Daniel Gillon represents public and private companies in corporate and securities matters, including private financings, public offerings, mergers and acquisitions, SEC reporting and compliance, and corporate governance. He also advises biotechnology, pharmaceutical, and other life sciences companies on licensing and commercial agreements.

Download full bio 


  • Structure Therapeutics – $185.3 Million IPO 

  • CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion 

  • Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion 

  • Mirum Pharmaceuticals – $92 Million Follow-on Offering 

  • Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion 


  • Duke University School of Law
    JD, cum laude, 2021

  • University of Washington
    MS, Aquatic & Fishery Sciences

  • Duke University
    BS, Biology
    with distinction, 2011

Admissions & Credentials